THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO
$24,132,383
| Recipient | AMGEN INC. UEI D92HARF1LKA9 |
|---|---|
| Award ID | 75A50119C00061 |
| Award amount | $24,132,383 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AN73 |
| Start date | Sep 26, 2019 |
| End date | Sep 10, 2025 |
| Place of performance | NEWBURY PARK, CA |
| Record updated | Jul 20, 2022 |
View the official award record
More awards won by AMGEN INC.
NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS)
Department of Health and Human Services · $7,290,924 · Aug 28, 2023
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids